Fig. 3.

Preventive effects of systemic or orally administered nucleoside phosphonates or vehicle on development of LV dysfunction after infarction in mice. a and b Infarct sizes were determined for groups receiving infusions or oral gavages. c and e Cardiac infarction resulted in decreased FS and EF, respectively, compared with the sham group. Systemic subcutaneous infusion of MRS2925, MRS2978 or MRS4074 (10 μM in the mini-pump) caused a higher FS and EF than vehicle treatment. The data on MRS4074 were similar to those previously published [12]. d and f. When MRS2978 (1 mg/kg) and MRS4074 (3 mg/kg) and MRS2925 (3 mg/kg) were given by oral gavage, MRS2978 and MRS4074 but not MRS2925 significantly improved LVFS and LVEF, respectively. *P < 0.05